- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01814098
An Efficacy and Safety Study of Escitalopram Long-Term Treatment in Major Depressive Disorder With Associated Anxiety Symptoms (Lexapro)
Escitalopram in the Long-term Treatment of Major Depressive Disorder With Associated Anxiety Symptom
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Beijng, China
-
Changsha, China
-
Hangzhou, China
-
Nanjing, China
-
Shanghai, China
-
Shenyang, China
-
Shijiazhuang, China
-
Tianjin, China
-
Wenzhou, China
-
Wuhan, China
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participant must be willing and able to give written informed consent
- Participant currently suffering from Major Depressive Disorder (MDD) with anxious symptoms including participant with first MDD episode, and relapsed participant with new episode
- Participant with minimum score at baseline of 22 on the Montgomery-Asbery Depression Rating Scale (MADRS) and minimum score at baseline of 14 on Hamilton Anxiety Rating (HAM-A) scales
- Female participant must be surgically sterile, or practicing an effective method of birth control before entry and throughout the study
Exclusion Criteria:
Participant who has continuously taken psychoactive substances, antidepressants, anxiolytics, monoamine oxidase inhibitors (MAOIs), psychoactive herbal remedies, lithium, electroconvulsive therapy (ECT) carbamazepine in the past 2 weeks before the baseline visit - Participants with MDD, requiring treatment systematically within past 2 months from baseline - Participants who has contraindication to escitalopram - Participant has primary or comorbid diagnoses of schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations [imagining things], and withdrawal into the self), schizoaffective disorder (a mixed psychiatric disorder relating to a complex psychotic state that has features of both schizophrenia and a mood disorder such as bipolar disorder), bipolar disorder, or dementia (mental decline) - Participant who has a significant risk of suicide on clinical assessment or has made a serious suicide attempt within the past 6-month
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Escitalopram
Escitalopram tablets will be administered orally at 10 milligram per day (mg/day).
The dose may be increased to maximum of 20 mg/day depending on Investigators discretion for 24 weeks
|
Escitalopram tablets will be administered orally at 10 milligram per day (mg/day).
The dose may be increased to maximum of 20 mg/day depending on Investigators discretion for 24 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Remission According to Montgomery-Asbery Depression Rating Scale (MADRS) and Hamilton Anxiety Scale (HAM-A)
Time Frame: Week 24
|
Remission is defined as MADRS total score =<10 and HAM-A score =<7.
MADRS measures depression severity and detects changes due to antidepressant treatment.
It consists of 10 items, each scoring from 0 (not present) to 6 (severe).
Total score= 0-60.
Higher scores indicate more severe condition.
HAM-A is 14-item scale measuring anxiety in individuals.
Each question reflects a symptom of anxiety (physical and mental symptoms).
The answers range from 0 (complete lack of symptom) to 4 (very severe show of anxiety with that symptom).
Total score= 0-56.
Higher scores indicate a more severe condition.
|
Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Showing Response
Time Frame: Week 24
|
Response is defined as having more than or equal to 50 percent decrease from baseline of MADRS total score.
The MADRS is a scale designed to measure depression severity and detects changes due to antidepressant treatment.
The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60.
Higher scores represent a more severe condition.
|
Week 24
|
Change From Baseline in MADRS Total Score at Week 24
Time Frame: Baseline and Week 24
|
The MADRS is a scale designed to measure depression severity and detects changes due to antidepressant treatment.
The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60.
Higher scores represent a more severe condition.
|
Baseline and Week 24
|
Change From Baseline of Single Rating Item in MADRS Total Score at Week 24
Time Frame: Baseline and Week 24
|
The MADRS is a scale designed to measure depression severity and detects changes due to antidepressant treatment.
The test consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total score of 60.
Higher scores represent a more severe condition.
|
Baseline and Week 24
|
Change From Baseline in Hamilton Depression Rating Scale (HAMD)-17 Score at Week 24
Time Frame: Baseline and Week 24
|
The depressive symptoms will be assessed using the 17-item HAMD scale, which provides a total score (0-52) (sum of the scores of all 17 items ).
For total score of each item, higher score indicates severity of depressive symptom.
|
Baseline and Week 24
|
Change From Baseline in Hamilton Anxiety Scale (HAM-A) Score at Week 24
Time Frame: Baseline and Week 24
|
The HAM-A is a 14-item scale designed to measure anxiety in individuals,which provide a total score of 0-56.
Higher scores indicate a more severe condition.
Each question reflects a symptom of anxiety and physical as well as mental symptoms are represented.
The answers range from 0 which signifies a complete lack of that symptom to 4, which indicates a very severe show of anxiety with that symptom.
|
Baseline and Week 24
|
Change From Baseline of Single Rating Item in HAM-A at Week 24
Time Frame: Baseline and Week 24
|
The HAM-A is a 14-item scale designed to measure anxiety in individuals,which provide a total score of 0-56.
Higher scores indicate a more severe condition.
Each question reflects a symptom of anxiety and physical as well as mental symptoms are represented.
The answers range from 0 which signifies a complete lack of that symptom to 4, which indicates a very severe show of anxiety with that symptom.
|
Baseline and Week 24
|
Change From Baseline in Clinical Global Impression Score (CGI-S) at Week 24
Time Frame: Baseline and Week 24
|
The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant.
A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants".
Higher scores indicate worsening.
|
Baseline and Week 24
|
Change From Baseline in Short Form-12 (SF-12) Score at Week 24
Time Frame: Baseline and Week 24
|
The SF-12 consists of eight scaled scores, which are the weighted sums of the questions in their section.
The eight sections are: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health Each item is scored into on a 0-100 range.
All items are scored so that a high score defines a more favorable health state.
|
Baseline and Week 24
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Pathologic Processes
- Mood Disorders
- Depression
- Depressive Disorder
- Disease
- Depressive Disorder, Major
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Antidepressive Agents
- Antidepressive Agents, Second-Generation
- Citalopram
Other Study ID Numbers
- CR016381
- ESCITALDEP4002
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Disorder, Major
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on Escitalopram
-
First Affiliated Hospital of Zhejiang UniversityRecruitingAdolescent | Depressive DisorderChina
-
Perry RenshawTerminatedDepression | Substance Use | Dual DiagnosisUnited States
-
University of NebraskaRecruiting
-
Rigshospitalet, DenmarkUniversity of Cambridge; Lundbeck FoundationCompleted
-
Ryerson UniversityUnknownInsomnia | Major Depressive DisorderCanada
-
Centre Hospitalier Universitaire VaudoisNot yet recruitingPharmacogenetic Testing
-
Shanghai 7th People's HospitalNot yet recruitingDepressive Disorder, MajorChina
-
Shanghai Mental Health CenterJiangsu Nhwa Pharmaceutical Co., Ltd.Completed
-
Shanghai Mental Health CenterRecruiting
-
University of PennsylvaniaWashington University School of MedicineCompleted